Area of research
Oncology · Immunology
Research interest
Research interests include Cancer Immunotherapy and Biomarkers, Immunotherapy and Immune Responses, Tuberculosis Research and Epidemiology, and CAR-T cell therapy research.
Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Author Correction: Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers
Compartmental Analysis of T-cell Clonal Dynamics as a Function of Pathologic Response to Neoadjuvant PD-1 Blockade in Resectable Non–Small Cell Lung Cancer
Persistent mutant oncogene specific T cells in two patients benefitting from anti-PD-1
Neoadjuvant PD-1 Blockade in Resectable Lung Cancer
The Mutation-Associated Neoantigen Functional Expansion of Specific T Cells (MANAFEST) Assay: A Sensitive Platform for Monitoring Antitumor Immunity
Suppressor Cell–Depleting Immunotherapy With Denileukin Diftitox is an Effective Host-Directed Therapy for Tuberculosis
Indole-2-carboxamide-based MmpL3 Inhibitors Show Exceptional Antitubercular Activity in an Animal Model of Tuberculosis Infection
Inhibition of innate immune cytosolic surveillance by an M. tuberculosis phosphodiesterase
A bacterial cyclic dinucleotide activates the cytosolic surveillance pathway and mediates innate resistance to tuberculosis
Aerosol Mycobacterium tuberculosis Infection Causes Rapid Loss of Diversity in Gut Microbiota
Synthetic Lethality Reveals Mechanisms of Mycobacterium tuberculosis Resistance to β-Lactams
Indoleamides are active against drug-resistant Mycobacterium tuberculosis
Preliminary Structure–Activity Relationships and Biological Evaluation of Novel Antitubercular Indolecarboxamide Derivatives Against Drug-Susceptible and Drug-Resistant Mycobacterium tuberculosis Strains
Pharmacokinetic and <i>In Vivo</i> Efficacy Studies of the Mycobactin Biosynthesis Inhibitor Salicyl-AMS in Mice
Successful Shortening of Tuberculosis Treatment Using Adjuvant Host-Directed Therapy with FDA-Approved Phosphodiesterase Inhibitors in the Mouse Model
Risk of Tuberculosis Reactivation With Tofacitinib (CP-690550)
Isoniazid resistance without a loss of fitness in Mycobacterium tuberculosis
Rv2190c, an NlpC/P60 Family Protein, Is Required for Full Virulence of Mycobacterium tuberculosis